Randomized Trialhigh evidence

Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial.

The Lancet. Oncology·January 1, 2026·PMID 41449147

Why it matters

This long-term analysis establishes a clear standard of care for IDH-mutant anaplastic astrocytoma: radiotherapy followed by 12 cycles of adjuvant temozolomide, without concurrent temozolomide. It also reinforces the prognostic and predictive importance of IDH mutation status in guiding treatment decisions.

Infographic summary of Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial.
Visual abstract · MedLit

The papers that matter, first.

MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.

§

MedLit · Evidence, Distilled